Sun Pharma Advanced Research Company share news, announcements and annual reports
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Sun Pharma Advanced Research Company Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2007
Last close ₹176.46down ₹6.52 (3.56%)BSE ₹176.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹182.98.
30 Oct: open ₹183.90, high ₹183.90, low ₹175.25
52-week range of traded prices to 30 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,727 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,50,81840.4% delivered
Sun Pharma Advanced Research Company share news and announcements
577 announcements, routine notices left out, newest first. Page 10 of 12.
Jun 2014
25 Jun · Meeting
Register of Members and Share Transfer Books of the Company will be closed from July 26, 2014 to July 31, 2014 (both days inclusive) for the purpose of holding of Annual General Meeting of the Company to be held on July 31, 2014.
May 2014
Apr 2014
30 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated,"There is no event which will have a bearing on the performance/operations of the Company nor any price sensitive information of the Company which are reportable under clause 36 or any other clause of the listing agreement with the exchanges which are not shared with the Exchanges."
Mar 2014
24 Mar · Updates
Members of the Exchange are hereby informed that 10,254 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. March 26, 2014.
Feb 2014
Jan 2014
20 Jan · Updates
Members of the Exchange are hereby informed that 33,120 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. January 22, 2014.17 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2013.
Dec 2013
Nov 2013
25 Nov · Updates
Members of the Exchange are hereby informed that 2852 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. November 27, 2013.
Oct 2013
29 Oct · Results
15 Oct · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the second quarter /half year ended September 30, 2013.
Aug 2013
29 Aug · Updates
Members of the Exchange are hereby informed that 4,114 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. September 02, 2013.
Jul 2013
23 Jul · Updates
Members of the Exchange are hereby informed that 4856 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. July 25, 2013.16 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2013.8 Jul · Meeting
Company has fixed Book Closure from July 26, 2013 to July 30, 2013 for the purpose of Annual General Meeting of the Company to be held on July 30, 2013.
Jun 2013
27 Jun · Conversion
With reference to the Company's earlier announcement regarding Final Call Notice on the 29588056 partly paid Equity Shares of the Company allotted on October 03, 2012 pursuant to the Rights Issue, the Company has further converted 101972 partly paid equity shares into fully paid up equity shares, allotted pursuant to the Rights Issue, on receipt of the Final Call money payment, for the period from May 15, 2013 to June 12, 2013. In view of the above, trading in the above 101972 equity shares converted to fully paid up of the company shall be available under the existing fully paid ISIN No. - INE232I01014 of the Company, with effect from June 28, 2013. The remaining partly paid shares shall he converted to fully paid shares as and when the Company receives the Final call money from the respective shareholders.26 Jun · Updates
Members of the Exchange are hereby informed that 101972 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. June 28, 2013.11 Jun · Updates
Members of the Exchange are hereby informed that 18830 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. June 13, 2013.
May 2013
14 May · Results
8 May · Updates
Members of the Exchange are hereby informed that 36323 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. May 10, 2013.
Apr 2013
26 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2013.11 Apr · Updates
Members of the Exchange are hereby informed that 29315664 partly paid up equity shares of Sun Pharma Advanced Research Company Limited has become fully paid up on receipt of balance call money. In view of the above, trading in above fully paid up shares shall be available under the ISIN No. - INE232I01014 w.e.f. April 15, 2013.
Mar 2013
Feb 2013
1 Feb · Suspension of partly paid up equity shares
Members of the Exchange are hereby informed that the trading in the Partly Paid Shares (Series E1) of Sun Pharma Advanced Research Company Limited shall be suspended w.e.f. February 15, 2013 (i.e. closing hours of trading on February 14, 2013) on account of payment of first and final call money.
Jan 2013
28 Jan · Corporate action
Board of Directors at their meeting held on January 24, 2013 have considered and decided to make the Final Call on the partly paid Equity Shares of the Company allotted pursuant to the Rights Issue, for balance amount of Rs.27 per share (comprising of Re. 0.40 per share towards face value and the balance of Rs. 26.60 towards the premium) and fixed February 18, 2013 as the Record date for the purpose of determining the shareholders eligible for payment of Final Call. The period for payment of the Final Call money has been fixed from March 1, 2013 to March 21,2013.9 Jan · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter ended December 31, 2012.
Dec 2012